Chemotherapy is a leading intervention against cancer. Albeit highly effective, chemotherapy has a multitude of deleterious side-effects including skeletal muscle wasting and fatigue, which considerably reduces patient quality of life and survivability. As such, a defence against chemotherapy-induced skeletal muscle dysfunction is required. Here we investigate the effects of oxaliplatin (OXA) treatment in mice on the skeletal muscle and mitochondria, and the capacity for the Poly ADP-ribose polymerase (PARP) inhibitor, BGP-15, to ameliorate any pathological side-effects induced by OXA. To do so, we investigated the effects of two weeks of OXA (3mg/kg) treatment with and without BGP-15 (15mg/kg). OXA induced a 15% (p<0.05) reduction in lean tissue mass without significant changes in food consumption or energy expenditure. OXA treatment also altered the muscle architecture, increasing collagen deposition, neutral lipid and Ca2+ accumulation; all of which were ameliorated with BGP-15 adjunct therapy. Here, we are the first to show that OXA penetrates the mitochondria, and, as a possible consequence of this, increases mtROS production. These data correspond with reduced diameter of isolated FDB fibres and shift in the fibre size distribution frequency of TA to the left. There was a tendency for reduction in intramuscular protein content, albeit apparently not via Murf1 (atrophy)- or p62 (autophagy)- dependent pathways. BGP-15 adjunct therapy protected against increased ROS production, improved mitochondrial viability 4-fold and preserved fibre diameter and number. Our study highlights BGP-15 as a potential adjunct therapy to address chemotherapy-induced skeletal muscle and mitochondrial pathology.
Sorensen, J. C., Petersen, A. C., Timpani, C. A., G Campelj, D., Cook, J., Trewin, A. J., Stojanovska, V., Stewart, M., Hayes, A., & Rybalka, E. (2017). BGP-15 protects against Oxaliplatin-induced skeletal myopathy and mitochondrial reactive oxygen species production in mice. Frontiers in Pharmacology, 8, . https://doi.org/10.3389/fphar.2017.00137